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Abstract
Background: The protease uPA and its inhibitor PAI-1 play major roles in hemostasis and are also involved in
cancer progression. This is mainly caused by their ability to degrade extracellular matrix-facilitating tumor cell
migration. This study aimed to investigate the impact of uPA/PAI-1 and disseminated cytokeratin-positive cells
(dCK+) on the outcome and the existence of synergistic effects.
Methods: We retrospectively analyzed a cohort of 480 breast cancer cases with known uPA/PAI-1 and dCK+ status.
uPA/PAI-1 was tested on fresh tumor samples using a commercial ELISA test. Bone marrow aspirates were
investigated immunocytochemically for CK18.
Results: DCK+ cells were identified in 23% of cases. uPA positivity was significantly associated with the occurrence
of dCK+ cells (P = 0.028). uPA and PAI-1 were significantly associated with outcome in the subgroup of early-stage
cases without chemotherapy. DCK+ cells alone were not prognostic. However, we found synergistic effects. In the
subgroup of node-negative cases with and without chemotherapy, the prognostic impact of uPA and PAI-1 was
enhanced in cases with additional dCK-positivity (triple +). In cases without chemotherapy, triple-positive status was
independently prognostic (HR: 9.3 CI: 1.1–75) next to T stage.
Conclusions: uPA and PAI-1 seem to influence the metastatic potential of dCK+ cells, which underlines its
important role in tumor progression.
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Background
Breast cancer is the most common malignant tumor and
the leading cause of cancer-related death in females in
Germany [1]. Prognosis estimation and therapy stratifi-
cation are mainly based on tumor grade, stage, hormone
receptor status, HER2 status, and proliferation rate [2].
Next to those well-established prognostic and predictive
markers, several new approaches have been pursued to
further improve the prediction of outcome and therapy
response in early breast cancer stages. Several multigene
assays for fresh and formalin-fixed paraffin-embedded
(FFPE) tissue samples have been developed and inte-
grated into clinical practice [3]. The individual immune
response has also gained increasing attention in breast
cancer as it has in many other entities. Both outcome
and response to chemotherapy are influenced by the
microenvironment. Denkert al. showed that the extent
of tumor-infiltrating lymphocytes is associated with the
response to neoadjuvant chemotherapy [4]. Cytotoxic T-
cells play an important role in tumor surveillance. The
ability of tumors to escape from this surveillance is one
of the hallmarks of cancer defined by Hanahan and
Weinberg [5]. Matrix degradation is another way to fa-
cilitate tumor progression. In this context, the plasmino-
gen/plasmin system has an important function. This
system consists of several components, including uPA,
which promotes the activation of plasminogen to plas-
min, and the uPA-receptor (uPAR) as well as PAI-1 and
PAI-2, which function as inhibitors of uPA. uPA, uPAR,
and PAI-1 have been found to be important prognostic
and predictive biomarkers of tumor progression. Next to
their function in matrix degradation, several additional
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effects, such as activation of proliferation, anti-apoptosis,
and angiogenesis have been discovered. This is very
likely the reason for the adverse effect of PAI-1 that
otherwise would be expected to be cancer suppressive.
The prognostic relevance of the plasminogen/plasmin
system has been reported in many cancer entities [6].
However, only in breast cancer has the evidence reached
a sufficient level for general recommendations regarding
its clinical use [7]. High levels of matrix-degrading pro-
teases promote tumor cell migration and dissemination.
Circulating tumor cells in the blood stream or dissemi-
nated cells in the bone marrow are believed to be the
origin of distant metastases. Therefore, their detection
can serve as biomarkers indicating an increased risk of
disease progression. While testing of circulating tumor
cells has not yet been introduced into the clinical rou-
tine, many studies have shown its clinical relevance in
several cancer entities, including breast cancer. In the
latter, it was shown to be prognostic and helpful in mon-
itoring the response of adjuvant therapy [8]. Given the
function of proteases in cancer, an association between
the level of uPA and PAI-1 and the occurrence of dis-
seminated tumor cells could be assumed. The aim of this
retrospective study was to evaluate the relationship and
potential interaction of the biomarkers uPA/PAI and dis-
seminated cytokeratin-positive (dCK+) cells in the bone
marrow.
Methods
Patients
Patients with breast cancer treated in the Klinikum
Augsburg between 1999 and 2010 were included in this
study. Bone marrow aspiration by puncture of both iliac
bones was performed in all patients in the operating
room right before lumpectomy or mastectomy, respect-
ively. Informed and written consent for this procedure
was obtained from all patients. Follow-up data were pro-
vided by the clinical and population-based cancer regis-
try of Augsburg. Additional information, including data
concerning adjuvant therapy, were obtained from the
clinical files which were screened for each patient. Neo-
adjuvant chemotherapy was a criterion of exclusion. The
study was approved by the internal review board of the
Klinikum Augsburg. Raw data are available from an
open repository.
Immunocytochemical evaluation of circulating CK+ cells
in the bone marrow
The samples were processed immediately after bone mar-
row aspiration. The technique has been described previ-
ously. In brief, the protocol for preparing the cytological
samples was initially established for the detection of CK+
cells in bone marrow aspirates [9, 10]. The mononuclear
cells were separated by Ficoll–Hypaque density gradient
centrifugation (density, 1.077 g per mole) at 900×g for 30
min. The cells were then washed and centrifuged at 150×g
for 5min. Approximately 1 × 106 cells were placed on
each glass slide.
To detect epithelial cells within the peripheral blood, a
monoclonal antibody against cytokeratin 18 (Clone CK18
(Clone CK2), 1: 100; Chemicon, Hofheim, Germany) was
used. The reactions were developed with the alkaline
phosphatase anti–alkaline phosphatase (APAAP) tech-
nique combined with a new fuchsin stain to indicate anti-
body binding, as previously described [9, 10]. CK+ cells
and clusters were counted manually (Fig. 1). All slides
were screened by an experienced technician. All positive
cases were confirmed by a hemato-oncologist (DO). Data
concerning interobserver agreement between these two
investigators are not available.
uPA/PAI-1 ELISA testing
The lumpectomy or mastectomy specimens were
brought to the laboratory of the pathology department
immediately after resection without time delay. Repre-
sentative samples were obtained from the fresh speci-
mens after thinly slicing, based on macroscopic and
palpatory examination. Attention was paid to avoid sam-
pling areas with or near core biopsy defect. For the
evaluation of the tissue levels of uPA/PAI-1, a commer-
cial enzyme-linked immune sorbent assay (ELISA) test
(Femtelle Test (EF 899), Sekisui Diagnostics, Stamford,
CT) was used. The test was conducted according to the
protocol recommended by the manufacturer and has
been described previously [4]. In brief, frozen tissue
samples were disrupted by mechanical force under per-
manent cooling. Tris-Buffer, supplemented with the
non-ionic detergent Triton X-100, was used to extract
the tumor cell cytosol. The suspensions were centrifuged
to separate the soluble fractions from the cell debris.
The total protein concentrations of the cytosolic frac-
tions were measured. On day 2, a diluted tissue extract
was added to antibody-coated microwells and incubated
overnight. On day 3, detection antibodies were added
and incubated. After another incubation step with the
enzyme conjugates, the reactions were stopped with 0.5
M of H2SO4, and the absorption of the solution was
measured using a microwell reader at 450 nm. The levels
of uPA and PAI-1 were expressed in nanograms per
milligram (ng/mg) of tumor protein. The cut-off-level
for uPA and PAI-1 were 3 and 14 ng/mg protein, re-
spectively, which are the same cut-offs routinely used in
clinical settings [11]. Cases with values under the cut-
offs were classified as negative and all others as positive.
Statistical analysis
uPA and PAI values were categorized as positive and
negative based on the defined cut-offs (3 and 14 ng/mg
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protein, respectively). All calculations were performed
using those dichotomized values.
The Mann-Whitney rank sum test was used to com-
pare numeric values. Correlations were calculated with
Pearson Product Correlation. Tabulated data were com-
pared using the chi-squared (χ2) test. For the survival
analysis, Kaplan-Meier curves were calculated, and dif-
ferences were analyzed with the log-rank test. The mean
overall survival times were calculated because the
median survival was not reached in most analyses. For
the determination of the median follow-up time, the
method of Schemper and Smith [12] was used. The Cox
regression proportional hazards model was used for the
multivariate analysis of cancer-specific analysis. All cal-
culations were performed using the Sigma Plot 13.0 soft-
ware package (Systat, Richmond, VA, USA). P-values
< 0.05 were considered significant. For the survival ana-
lyses, we calculated additional thresholds considering
the issue of multiple testing using the procedure of
Bonferroni-Holm [13].
Results
Patients and correlations with clinico-pathological factors
The case characteristics are summarized in Table 1. A
total of 480 patients primarily diagnosed and treated
between 1999 and 2010 were included, with 80% of
the cases from the years 2003 to 2006. The median
follow-up time was 81 months (CI: 76–86 months).
Presence of dCK+ cells was associated with the oc-
currence of lymph node metastases (P < 0.005). There
was a trend toward a higher rate of dCK+ cells with
increasing pT-stage (P = 0.100). uPA and PAI-1 levels
were significantly associated with grade (P < 0.001
and P < 0.007) and progesterone receptor negativity
(P = 0.01 and P = 0.023). uPA also showed an associ-
ation with estrogen receptor negativity (P = 0.04),
while PAI-1 showed only a trend in this direction
(P = 0.06). Furthermore, a significant correlation with
HER2 positivity was found for PAI-1 (P = 0.022).
According to national AGO guidelines, chemotherapy
was administered in a high frequency in cases with ele-
vated uPA and PAI-1 levels (P < 0.01 and P < 0.009).
Nevertheless, there was a considerable number of
patients who did not receive chemotherapy despite ele-
vated protease levels (52 and 81 patients).
Correlation of proteases and dCK+ cells with survival
Complete cohort
Analyzing the whole cohort (n = 480), we identified an
association between uPA, grading, and dCK+ cells with
dCK+ rates of 18.8% vs 27.7% in uPA-negative and
-positive cases, respectively (P = 0.028; BHST 0.013).
There was a trend toward reduced overall survival in pa-
tients with high PAI-1 levels with mean overall survival
times of 112 months (CI: 104–119 months) versus 118
months (CI: 111–126 months); (P = 0.128 BHST 0.006).
Neither uPA- nor dCK+ cell analysis was prognostic
with identical Kaplan-Meier curves for positive and
negative cases.
Cases with chemotherapy
In cases with administered chemotherapy (N = 291), nei-
ther the proteases nor dCK+ cells were prognostic. Also,
cases with triple positivity of uPA, PAI-1 and dCK+ cells
did not show a different outcome compared to the other
constellations.
Fig. 1 Immunocytochemically detected disseminated cells a) Three cytokeratin-positive (CK+) single cells; b) A cluster of 13 cytokeratin-positive
cells. Note: These stainings were performed without counter-staining; therefore, the nuclei of the tumor cells are visible only as empty spaces
within the cells, which explains different amounts of cytokeratin staining
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Table 1 .
Complete collection
n = 480 (100%)
Positive dCK+ cells
n = 110 (23%)
Negative dCK+ cells
n = 370 (77%)
UPA pos.
n = 220 (46%)
UPA neg n = 260
(54%)
PAI 1 pos.
n = 326 (68%)
PAI 1 neg. n = 154
(32%)
Age
< 51
years
115 (24%) 27 (25%) 88 (24%) 50 (23%) 65 (25%) 78 (24%) 37 (24%)
51–58
years
76 (16%) 19 (17%) 57 (15%) 39 (18%) 37 (14%) 50 (15%) 26 (17%)
59–66
years
129 (27%) 28 (25%) 101 (27%) 58 (26%) 71 (27%) 84 (26%) 45 (29%)
67–75
years
111 (23%) 25 (23%) 86 (23%) 51 (23%) 60 (23%) 78 (24%) 33 (21%)
> 75
years
49 (10%) 11 (10%) 38 (10%) 22 (10%) 27 (10%) 36 (11%) 13 (8%)
p = 0.9 n.s p = 0.8 n.s. p = 0.8 n.s.
Tumor Size
pT1 244 (51%) 52 (47%) 192 (52%) 116 (53%) 128 (49%) 166 (51%) 78 (51%)
pT2 191 (40%) 45 (41%) 146 (39%) 88 (40%) 103 (40%) 133 (41%) 58 (38%)
pT3 33 (7%) 11 (10%) 22 (6%) 11 (5%) 22 (8%) 20 (6%) 13 (8%)
pT4 11 (2%) 1 (1%) 10 (3%) 4 (2%) 7 (3%) 7 (2%) 4 (3%)
unknown
1 (0%) 1 (1%) 0 (0%) 1 (0%) 0 (0%) 0 (0%) 1 (1%)
p = 0.1 n.s. p = 0.4 n.s. p = 0.5 n.s.
Grading
G1 45 (9%) 11 (10%) 34 (9%) 14 (6%) 31 (12%) 31 (10%) 14 (9%)
G2 275 (57%) 61 (55%) 214 (58%) 111 (50%) 164 (63%) 172 (53%) 103 (67%)
G3 157 (33%) 37 (34%) 120 (32%) 94 (43%) 63 (24%) 122 (37%) 35 (23%)
unknown
3 (1%) 1 (1%) 2 (1%) 1 (0%) 2 (1%) 1 (0%) 2 (1%)
p = 0.9 n.s p < 0.001 sign. p < 0.007 sign.
Nodal Status
pN0 249 (52%) 53 (48%) 196 (53%) 112 (51%) 137 (53%) 171 (52%) 78 (51%)
pN1 148 (31%) 30 (27%) 118 (32%) 73 (33%) 75 (29%) 103 (32%) 45 (29%)
pN2 47 (10%) 10 (9%) 37 (10%) 22 (10%) 25 (10%) 29 (9%) 18 (12%)
pN3 29 (6%) 15 (14%) 14 (4%) 10 (5%) 19 (7%) 19 (6%) 10 (6%)
unknown
7 (1%) 2 (2%) 5 (1%) 3 (1%) 4 (2%) 4 (1%) 3 (2%)
p < 0.005 sign. p = 0.6 n.s. p = 0.8 n.s.
UICC-stage
stage I 147 (31%) 33 (30%) 114 (31%) 61 (28%) 86 (33%) 95 (29%) 52 (34%)
stage IIA 167 (35%) 30 (27%) 137 (37%) 84 (38%) 83 (32%) 121 (37%) 46 (30%)
stage IIB 68 (14%) 15 (14%) 53 (14%) 32 (15%) 36 (14%) 45 (14%) 23 (15%)
stage IIIA 46 (10%) 10 (9%) 36 (10%) 22 (10%) 24 (9%) 29 (9%) 17 (11%)
stage IIIB 2 (0%) 1 (1%) 1 (0%) 0 (0%) 2 (1%) 2 (1%) 0 (0%)
stage IIIC 27 (6%) 11 (10%) 16 (4%) 9 (4%) 18 (7%) 17 (5%) 10 (6%)
stage IV 21 (4%) 9 (8%) 12 (3%) 11 (5%) 10 (4%) 16 (5%) 5 (3%)
unknown
2 (0%) 1 (1%) 1 (0%) 1 (0%) 1 (0%) 1 (0%) 1 (1%)
p = 0.038 sign.* p = 0.352 n.s.* p = 0.437 n.s.*
Chemotherapie
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Node-negative cases
This subgroup comprised 249 cases. Again, a trend to-
wards impaired outcome was seen in cases with PAI-1
positivity with mean overall survival times of 114months
(CI: 111–126 months) and 126 months (CI: 117–135
months) (P = 0.081 BHST 0.007). A marginally signifi-
cantly different overall survival was found in uPA-
negative versus -positive cases with mean survival times
of 123months (CI: 116–130months) and 108 months
(CI: 100–116 months) (P = 0.065 BHST 0.008). The iden-
tification of dCK+ cells was not prognostic (Fig. 2a).
However, a significant difference, was found when com-
paring triple negative cases versus PAI-1-negative versus
PAI-1-positive cases with uPA- and PAI-1- positivity
(double positive) versus uPA-, PAI-1- and dCK+ cell
positivity (triple-positive) (P = 0.022 BHST 0.01) with
mean survival times of 127 months (Cl: 116–138
months), 126 months (CI: 117–135 months) (P = 0.045
BHST 0.01), 107 months (CI: 98–116 months), 115
months (CI: 108–122 months), and 90 months (CI:
75–105 months) (Fig. 2b). Pairwise Multiple Compari-
son Procedures (Holm-Sidak method) revealed signifi-
cant differences between triple positive cases and
PAI-negative cases (P = 0.014) and triple negative
cases (P = 0.036). All other combinations, especially
the comparison between double and triple positive
cases were not significant.
Node-negative cases without chemotherapy
In locally limited tumors without nodal involvement and
without known administration of adjuvant chemotherapy,
both proteases were highly significant prognostic factors
for overall survival (uPA: positive vs negative 91months
(CI: 78–103months) vs 119months (CI: 108–129
months); P = 0.006 (BHST 0.017) (Fig. 3a); (PAI-1: positive
vs negative 94months (CI: 84–103months) vs 125months
(CI: 114–136months); P = 0.004 BHST 0.025 (Fig. 3b).
Disseminated CK+ cells alone were not found to be
prognostic in this subgroup (dCK+ cells: positive vs
negative 90 months (CI: 89–120 months) vs 112
months (CI: 101–122 months); P = 0.617 (Fig. 3c).
However, triple-positive (PAI-1, uPA, dCK+ cells)
cases show a significantly (P = 0.002 BHST 0.05) worse
outcome compared to cases with less than three posi-
tive factors with mean overall survival times of 76
months (CI: 56–98 months) vs 114 (CI: 105–123
months) (Fig. 3d). Pairwise multiple comparison
procedures (Holm-Sidak method) revealed only a
Table 1 . (Continued)
Complete collection
n = 480 (100%)
Positive dCK+ cells
n = 110 (23%)
Negative dCK+ cells
n = 370 (77%)
UPA pos.
n = 220 (46%)
UPA neg n = 260
(54%)
PAI 1 pos.
n = 326 (68%)
PAI 1 neg. n = 154
(32%)
yes 291 (61%) 65 (59%) 226 (61%) 149 (68%) 142 (55%) 210 (64%) 81 (53%)
no 145 (30%) 36 (33%) 109 (29%) 52 (24%) 93 (36%) 84 (26%) 61 (40%)
unknown
44 (9%) 9 (8%) 35 (9%) 19 (9%) 25 (10%) 32 (10%) 12 (8%)
p = 0.7 n.s. p < 0.01 sign. p < 0.009 sign.
Estrogen
negative 57 (12%) 14 (13%) 43 (12%) 35 (16%) 22 (8%) 46 (14%) 11 (7%)
positive 419 (87%) 94 (85%) 325 (88%) 183 (83%) 236 (91%) 278 (85%) 141 (92%)
unknown
4 (1%) 2 (2%) 2 (1%) 2 (1%) 2 (1%) 2 (1%) 2 (1%)
p = 0.4 n.s. p = 0.04 sign. p = 0.06 n.s.
Progesteron
negative 63 (13%) 15 (14%) 48 (13%) 40 (18%) 23 (9%) 52 (16%) 11 (7%)
positive 413 (86%) 93 (85%) 320 (86%) 178 (81%) 235 (90%) 272 (83%) 141 (92%)
unknown
4 (1%) 2 (2%) 2 (1%) 2 (1%) 2 (1%) 2 (1%) 2 (1%)
p = 0.4 n.s. p = 0.01 sign. p = 0.023 sign.
HER2-Status
negative 362 (75%) 82 (75%) 280 (76%) 158 (72%) 204 (78%) 236 (72%) 126 (82%)
positive 107 (22%) 26 (24%) 81 (22%) 57 (26%) 50 (19%) 84 (26%) 23 (15%)
unknown
11 (2%) 2 (2%) 9 (2%) 5 (2%) 6 (2%) 6 (2%) 5 (3%)
p = 0.8 n.s. p = 0.2 n.s. p = 0.022 sign.
= I vs. II vs. III vs. IV
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significant difference between the groups triple posi-
tive and one or none positive marker (P = 0.001), all
other combinations were not significantly different.
The survival was also shorter compared to cases with
elevation of both proteases. However, this difference
did not reach significance. Including PAI-1, uPA,
dCK+ cells, T-stage, and grade into a multivariate
analysis revealed T-stage (HR: 3.4 CI: 1.6–7.2) and
triple positivity (HR: 9.3 CI: 1.1–75) as independent
prognostic factors.
Discussion
In this study, we retrospectively evaluated the relation-
ship between and the potential interaction of uPA and
PAI-1, which are two members of the plasminogen/plas-
min system, and the occurrence of dCK + cells in in a
cohort of 481 breast cancer cases. uPA and PAI-1 testing
for therapy decisions in early breast cancer has been rec-
ommended for its routine use in early-stage invasive
breast cancer by the American Society of Clinical Oncol-
ogy [7] as well as the German AGO guidelines [14].
There are several approaches to evaluate the different
factors of the plasmin/plasminogen system. These in-
clude immunohistochemical, ELISA- and reverse tran-
scription polymerase chain reaction (RT-PCR)
techniques. In the context of cancer, plasma and tumor
tissue as well as tumor cells can be evaluated. For this
study, a commercial ELISA test that found broad clinical
acceptance analyzing fresh tumor tissue was used [15,
16]. This guaranteed a standardized evaluation. Despite
this, the adherence to adjuvant chemotherapy in cases of
elevated proteinases was low, with approximately 25%
cases without adjuvant therapy in the high-risk groups
(Table 1). Recently, we and others evaluated the effect of
proteinases and multigene-assay testing on therapy deci-
sions and concordantly found a lower impact of protein-
ase testing [17, 18]. We have no data elucidating the
reason for that. One reason might be that the proportion
of high-risk cases is rather high, and clinicians may be
concerned that the risks due to adjuvant therapy might
be higher than the acceptable benefits.
For the evaluation of circulating tumor cells, many dif-
ferent techniques have been developed. This concerns
techniques of detection as well as the evaluated com-
partment of peripheral blood versus bone marrow. We
used immunocytochemistry to detect cytokeratin 18-
positive epithelial cells [10]. The technique of immuno-
histochemistry (CK18) based was well established in our
laboratory and revealed reliable results [9, 19]. Using the
same technique in colon specimens, we also detected
positive cells in benign cases with diverticulitis [20].
Therefore, we think it is appropriate to avoid referring
to these cells as tumor cells instead of dCK+ cells.
Twenty-three percent of the cases in our collective were
dCK+. This is a slightly lower rate compared to the
pooled analysis including 4703 patients with a positivity
rate of 30.6%. The positivity rate in this study, however,
differed considerably between the contributing centers
Fig. 2 Overall survival in node-negative cases. a) Outcome dependent on the occurrence of disseminated cytokeratin-positive cells (dCK+). b)
Outcome dependent on the occurrence of dCK+ cells and positivity of the proteases uPA and/or PAI-1 positivity is defined as tissue level above
the cut-off. Note: BHST = 0.01
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from 12.4 to 43.9%. Because of the availability of new
methods and generally easier access, more recently per-
formed studies have focused on CTC detection in per-
ipheral blood. The detection rates in peripheral blood
using modern techniques, such as the CellSearch™ sys-
tem, RT-PCR, or immunofluorescence staining [8, 21],
and evaluation of bone marrow and peripheral blood
have yielded conflicting results. Schindlbeck et al. found
comparable results when analyzing samples of peripheral
blood and bone marrow [22]. Molloy et al. reported an
additional adverse prognostic effect in cases in which
tumor cells in both compartments were detected [23].
Only a weak concordance between blood and bone mar-
row samples was reported by Fehm et al. [24].
The plasminogen/plasmin system plays a crucial role
in the degradation of several proteins, including fibrin,
which leads to the dissolution of fibrin clots. Through
cleavage, uPA activates plasminogen to plasmin, and
PAI-1 is the physiological inhibitor in this context. Next
to its function in fibrinolysis, this system is of high
Fig. 3 Overall survival in node-negative cases without chemotherapy. a) Outcome dependent on the tissue level of uPA BHST = 0.017. b)
Outcome dependent on the tissue level of PAI-1 BHST = 0.025. c) Outcome dependent on the occurrence of disseminated cytokeratin positive
cells (dCK+). d) Outcome dependent on the occurrence of dCK+ cells and positivity of the proteases uPA and PAI-1 BHST = 0.05
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importance for the process of wound healing, which is
the next step of repair after an injury. Here PAI-1 is not
just an inhibitor of uPA, but an active player with dis-
tinct functions [25]. At least to some extent, cancer pro-
gression can be understood as a misdirected form of
wound healing processes. The ability of uPA to degrade
extracellular matrix is believed to facilitate tumor cell
migration [26, 27]. Therefore, we assumed an association
between uPA tissue levels and the occurrence of dCK+
cells. Indeed, we have identified such a relationship with
a significantly higher rate (18.8% vs 27.7%) of dCK+
positivity in uPA-positive cases (P = 0.028). Such an
effect was also found for PAI-1, but it was considerably
lower (20.1% vs 24.2%) and did not reach significance.
During wound healing, PAI-1 is expressed at the edge
of an injury, stimulating attachment-detachment-
reattachment processes [25, 28]. For detachment and
cell migration, interaction between PAI-1 and uPA
and its receptor uPAR and the lipoprotein receptor-
related protein 1 (LRP1) is needed. This is a complex
system, and our data may indicate that uPA plays an
especially important role in the detachment of tumor
cells and tumor migration. To our knowledge, only a
few studies have addressed the topic of interaction
between uPA/aPAR or PAI-1 with circulating tumor
cells [29–31]. Mego et al. and Thomas et al. reported
in concordance to our results associations between
uPA and the occurrence of circulating tumor cells
[29, 30]. Meng et al. found an association between
HER2-postivitiy and uPA-expression on circulating
tumor cells [31]. We found a trend toward a higher
HER2-positivity in uPA-positive cases and a signifi-
cant association with PAI-1 positivity (Table 1). Asso-
ciation with circulating tumor cells and HER2
indicate an adverse effect. The prognostic significance
of uPA/PAI in tumor tissue has been confirmed in
several studies [16, 32, 33]. However, we emphasize
that it was not the main goal of our study to re-
evaluate the prognostic relevance of uPA/PAI-1. We
therefore evaluated uPA and PAI-1 separately. In our
case series, we found a clear trend toward poor over-
all survival in PAI-1-positive cases when we analyzed
the whole collective. In the subgroup of node-
negative cases, PAI-1 (P = 0.081) and uPA (P = 0,031)
showed prognostic relevance regarding overall sur-
vival. This prognostic effect was much stronger in the
subgroup of node-negative cases without chemother-
apy which is in accordance with the literature [15].
This is also in agreement with prior evidence [16, 34]
indicating that patients in early breast cancer stages
and those with elevated proteases benefit from
adjuvant chemotherapy. The presence of dCK+ cells
was associated with nodal status and by trend with
tumor size. However, it was not prognostic
concerning overall survival regardless of nodal status
and application of adjuvant chemotherapy. This is in
contrast to data from the literature using the same
method of cell detection [9, 19, 35]. The main differ-
ence compared to the most previously published stud-
ies is the choice of endpoint. Because of the
retrospective design, we have chosen overall survival,
while many other used disease-free or tumor-specific
survival, which might be more precise and therefore
ideal for a prospective approach. However, we pos-
sibly identified an additive effect when dCK+ cells
were identified in cases with uPA/PAI-1 positivity.
This finding must be considered with caution because
the difference between double and triple positive
cases lacked significance. In node-negative cases with-
out chemotherapy, triple positivity (uPA+; PAI-1+,
dCK+) and T-stage were the only independent prog-
nostic factors. This could indicate that uPA and PAI-
1 not only facilitate detachment and migration of
tumor cells but may also help those cells to persist
within the bloodstream and bone marrow and to de-
velop distant metastases. PAI-1 promotes angiopoesis
and inhibits p53-induced apoptosis [36], two major
hallmarks of cancer. Activation of invasion, a third
hallmark, has been mentioned above [5]. Fibrin is be-
lieved to protect cancer cells from immune surveil-
lance, which displays the fourth hallmark. Because
PAI-1 inhibits fibrinolysis, this is very likely to also
promote metastases formation [27, 37]. Additionally,
uPA/uPAR are mitogenic which is the 5th hallmark
[27]. This broad and very complex interaction be-
tween uPA, PAI-1, and dCK+ cells could explain the
observed additive and maybe even synergistic effects
of those three factors regarding outcomes of patients
in early breast cancer stages. However, this hypothesis
has not been proven by the data of this study and re-
quires further evaluation.
This study is limited by its retrospective design. In
this context, the results of the bone marrow evalu-
ation could not be re-evaluated, and we do not have
data concerning the interobserver agreement of the
two investigators. Being unable to control and/or
monitor the different factors that may influence such
a complex system makes it difficult to draw definitive
conclusions. Although our complete collective com-
prises a relatively large number of patients with a
considerable follow-up, the need to analyze subgroups
makes this collective still rather small. A further limi-
tation is the missing availability of further biomaterial
for additional analyses like co-expression of different
markers on dCK+ cells. Despite these limitations this
study could serve as a basis of further investigations
employing modern detection methods combined with
single cell analyses.
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Conclusions
Our results indicate a potential biological interaction be-
tween the protease uPA, its inhibitor PAI-1, and dCK+
cells and an independent prognostic effect. uPA and
PAI-1 were prognostic in the subgroup of node-negative
breast cancer patients without chemotherapy. The ad-
verse effect of an elevated proteolytic system may have
been counteracted by adjuvant chemotherapy. Our data
further underline the importance of the hemostatic sys-
tem for tumor progression. However, this hypothesis has
not been proven by the data of this study and requires
further evaluation.
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